Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Stocks Could Rise For Companies Investing In Immunotherapy Treatments
Seeking Alpha
Tuesday, February 19, 2013 - 10:12am
tags:
immunotherapy, Celgene, Bristol-Myers Squibb, OncoSec, ONYX Pharmaceuticals, Vical
Takeda Faces First Trial Over Actos Diabetes Drug in L.A.
Bloomberg
Tuesday, February 19, 2013 - 10:11am
tags:
Takeda, Actos, diabetes
Quintiles Confirms 'Go Public' Speculation with IPO and Predicts Rosy Future for CROs
Outsourcing Pharma
Tuesday, February 19, 2013 - 10:08am
tags:
IPOs, Quintiles, CROs
Why Forest Laboratories May Be About to Take Off
Motley Fool
Tuesday, February 19, 2013 - 10:07am
tags:
Forest Labs
Rexahn says to continue RX-3117 development with Teva
The Fly on the Wall
Tuesday, February 19, 2013 - 10:07am
tags:
Rexahn, RX-3117, Teva, RX-5902, Archexin
Will Sequester End Drug Approvals? Not Unless White House Wants it to
Forbes
Tuesday, February 19, 2013 - 10:05am
tags:
FDA, drug approvals
Vioxx and Diclofenac: Why Are Two Heart Risky Pain Drugs Viewed Differently?
Forbes
Tuesday, February 19, 2013 - 10:04am
tags:
Vioxx, diclofenac, Merck, Celebrex, Voltaren
4 Healthcare Stock Stories Starting Off the Short Week
Wall St. Cheat Sheet
Tuesday, February 19, 2013 - 9:58am
tags:
Novartis, AbbVie, St. Jude Medical, Amicus Therapeutics
Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Yahoo
Tuesday, February 19, 2013 - 9:54am
tags:
lixisenatide, Sanofi, FDA, diabetes, GLP-1 receptor
A Legit Reason To Give Amicus' Fabry Drug Another Chance
TheStreet.com
Tuesday, February 19, 2013 - 9:51am
tags:
Amicus, Fabry's disease, Amigal
Merck: Enjoy This Generous Yield
Seeking Alpha
Tuesday, February 19, 2013 - 9:46am
tags:
Merck
Outgoing chairman of Switzerland's Novartis foregoes $78 million golden parachute deal
Yahoo/AP
Tuesday, February 19, 2013 - 9:42am
tags:
Daniel Vasella, Novartis
Merck's Weakest Blockbuster?
Motley Fool
Tuesday, February 19, 2013 - 9:41am
tags:
Merck, Remicade, rheumatoid arthritis, AbbVie, Humira
Roche Alzheimer’s Push May Gain From Obama Brain-Mapping Plan
Bloomberg
Tuesday, February 19, 2013 - 9:39am
tags:
Roche, Alzheimer's disease, Eli Lilly, Brain Activity Map
Actelion Looks Within as Competition Lifts Drug Prices
Bloomberg
Monday, February 18, 2013 - 12:24pm
tags:
Actelion, pulmonary arterial hypertension, PAH, Tracleer
Vasella’s $78 Million Novartis Payout Boosts ‘Fat-Cat’ Crackdown
Bloomberg
Monday, February 18, 2013 - 12:22pm
tags:
Daniel Vasella, Novartis, executive pay
Anything Can Happen This Year For Celldex
Seeking Alpha
Monday, February 18, 2013 - 12:18pm
tags:
Celldex, breast cancer, CDX-110, CDX-111, Seattle Genetics
Omeros Corporation's Stock Has Potential To Double This Year
Seeking Alpha
Monday, February 18, 2013 - 12:13pm
tags:
Omeros, OMS302
What to Expect from DepoMed
Motley Fool
Monday, February 18, 2013 - 12:04pm
tags:
Depomed, earnings
NovaBay's Sugar Daddy, Galderma, Pushes Impetigo Treatment
Seeking Alpha
Monday, February 18, 2013 - 12:04pm
tags:
Galderma, impetigo, NovaBay Pharmaceuticals, NVC-422, South Africa

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.